lncRNA Expression Construct Induces Regulatory B Cells
Solution Overview
Problem
Current treatments for autoimmune diseases like systemic lupus erythematosus are often toxic, require ongoing treatment, and have limited efficacy, with a need for more specific therapies that restore immune tolerance to disease-associated autoantigens, particularly during the preclinical phase to prevent organ damage.
Innovation Solution
An expression construct encoding a human long noncoding RNA (lncRNA) sequence from the complement receptor 2 (CR2) gene, specifically the intron 1 sequence with a guanine→adenine transposition at position rs1876453, is used to augment the generation of regulatory B cells, enhancing antigen-specific immune tolerance by increasing CR1 levels in B cells, which are then administered to patients at risk for autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If global immunosuppression is used to treat autoimmune diseases, then immune responses are suppressed, but the risk of infection and malignancy increases and treatment efficacy is limited
Solution Approach 1:
The patent applies local quality by targeting specific B cell subsets (naive B cells) and specific antigens (autoantigens) rather than applying global immunosuppression. The expression construct is designed to be selectively expressed in B cells through B cell-specific promoters (Ig heavy chain promoter, Ig kappa enhancer), enabling localized therapeutic action that restores tolerance to autoantigens without broadly suppressing the immune system, thereby avoiding increased infection and malignancy risks
Solution Approach 2:
The patent uses an intermediary approach by introducing a long noncoding RNA expression construct that acts as a mediator to restore immune tolerance. The lncRNA serves as an intermediate molecule that modulates B cell responses to autoantigens, promoting the generation of regulatory B cells and reducing autoantibody production without requiring direct immunosuppressive intervention, thus achieving specific tolerance restoration with minimal side effects
2Reliability
If ongoing immunosuppressive treatment is administered, then disease activity is controlled, but the treatment requires continuous administration and has limited efficacy
Solution Approach 1:
The patent applies preliminary action by targeting naive B cells early in the immune response pathway, before they differentiate into pathogenic antibody-producing cells. By intervening at this early stage through selective expression of the lncRNA in naive B cells, the treatment prevents the development of autoimmune pathology rather than merely controlling established disease, potentially reducing or eliminating the need for ongoing immunosuppressive therapy
Solution Approach 2:
The patent enables self-service by designing an expression construct that utilizes endogenous B cell regulatory mechanisms. The lncRNA expression is controlled by B cell-specific regulatory elements (Ig heavy chain promoter, Ig kappa enhancer) that are naturally active in B cells, allowing the therapeutic to be self-regulating within the target cell population without requiring external control mechanisms or continuous dosing adjustments
3Reliability
If specific therapies targeting immune tolerance restoration are developed, then efficacy against autoantigens is improved, but the complexity of the treatment increases
Solution Approach 1:
The patent applies universality by designing a single expression construct that achieves multiple therapeutic functions simultaneously. The lncRNA expression construct controlled by B cell-specific regulatory elements can target multiple autoantigens through the natural B cell repertoire, restore immune tolerance, and promote regulatory B cell generation without requiring separate therapies for different targets, thereby reducing overall treatment complexity while maintaining high specificity
Solution Approach 2:
The patent uses copying by introducing a synthetic lncRNA expression construct that mimics and enhances endogenous protective mechanisms. The construct copies the function of protective alleles (such as CR2 variants associated with reduced SLE risk) by expressing lncRNAs that regulate B cell responses in a protective manner, providing a simplified therapeutic approach that replicates natural tolerance mechanisms rather than requiring complex engineered solutions
Data Source
AI summary
The present invention contemplates that complement receptor 1 and 2 may play a role in the induction of regulatory B cells under inflammatory conditions that accompany immune-mediated diseases. For example, long noncoding RNA may regulation transcription of the complement receptor I gene, thereby resulting in an induction and/or suppression of regulatory B cells. Such long noncoding RNA in mature B cells may be specifically targeted to modify complement receptor 1 levels and induce or suppress the generation of antigen-specific regulatory B cells, thereby modifying the course of immune mediated diseases including, but not limited to, autoimmune disease, cancer, and infection.